Literature DB >> 24997770

Changes of serum omentin-1 levels in normal subjects, type 2 diabetes and type 2 diabetes with overweight and obesity in Chinese adults.

Qiang Zhang1, Lei Zhu2, Min Zheng1, Chaohua Fan1, Yunhao Li1, Dan Zhang1, Yanming He1, Hongjie Yang3.   

Abstract

PURPOSE: Omentin-1 has been identified as interesting novel adipokines that may modulate insulin action. Its exact biological function is unclear. The aim of this study is to assay the levels of serum omentin-1 in normal subjects and type 2 diabetes mellitus (T2DM) with normal weight, overweight and obesity and to analyze the relationship between serum omentin-1 levels with body mass index (BMI), waist to hip ratio (WHR), glycosylated hemoglobin (HbA1c), plasma glucose, insulin resistance index (HOMA-IR) and serum lipid levels.
METHODS: There are eighty newly diagnosed type 2 diabetes patients, thirty-five type 2 diabetes patients with normal weight, twenty-nine type 2 diabetes patients with overweight, sixteen type 2 diabetes patients with obesity, and forty healthy control subjects were enrolled in this study. The levels of plasma glucose at fasting and 2-hour postprandial blood glucose and fasting serum levels of insulin, omentin-1and HbA1c were measured. HOMA-IR was calculated.
RESULTS: Serum omentin-1 levels were found to be significantly decreased in type 2 diabetes patients with normal weight (821.16 ± 312.50 ng/L), in type 2 diabetes patients with overweight (748.00±322.51 ng/L), and in type 2 diabetes patients with obesity (530.44±357.35 ng/L) compared with healthy control subjects (994.71±435.90 ng/L) at P<0.05. The level of serum omentin-1 was negatively correlated to BMI, HOMA-IR, WHR, fasting insulin (FINS), fasting plasma glucose (FPG), 2-hour postprandial blood glucose (2HPG), triglycerides (TG), and positively correlated to high-density lipoprotein (HDL). BMI was independent related factor that influenced the levels of serum omentin-1.
CONCLUSION: Decreased omentin-1 levels may contribute to the development of insulin resistance, T2DM and particularly to obesity in Chinese adults, however, its role in these diseases needs to be fully elucidated.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Adipokines; Insulin and diabetes; Insuline et diabète; Omentin; Omentine

Mesh:

Substances:

Year:  2014        PMID: 24997770     DOI: 10.1016/j.ando.2014.04.013

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  13 in total

1.  Effect of High-Intensity Interval Training on Plasma Omentin-1 Concentration in Overweight/Obese and Normal-Weight Youth.

Authors:  Nejmeddine Ouerghi; Mohamed Kacem Ben Fradj; Ikram Bezrati; Moncef Feki; Naziha Kaabachi; Anissa Bouassida
Journal:  Obes Facts       Date:  2017-08-05       Impact factor: 3.942

2.  Higher circulating omentin is associated with increased risk of primary cardiovascular events in individuals with diabetes.

Authors:  Corinna Niersmann; Maren Carstensen-Kirberg; Haifa Maalmi; Bernd Holleczek; Michael Roden; Hermann Brenner; Christian Herder; Ben Schöttker
Journal:  Diabetologia       Date:  2019-11-09       Impact factor: 10.122

3.  Increased Release of Proinflammatory Proteins in Primary Human Adipocytes and Activation of the Inflammatory NFĸB, p38, and ERK Pathways upon Omentin Treatment.

Authors:  Corinna Niersmann; Karin Röhrig; Matthias Blüher; Michael Roden; Christian Herder; Maren Carstensen-Kirberg
Journal:  Obes Facts       Date:  2020-04-06       Impact factor: 3.942

4.  Effects of High-Intensity Interval Training on Selected Adipokines and Cardiometabolic Risk Markers in Normal-Weight and Overweight/Obese Young Males-A Pre-Post Test Trial.

Authors:  Nejmeddine Ouerghi; Mohamed Kacem Ben Fradj; Martine Duclos; Anissa Bouassida; Moncef Feki; Katja Weiss; Beat Knechtle
Journal:  Biology (Basel)       Date:  2022-06-02

5.  Reduced beta 2 glycoprotein I prevents high glucose-induced cell death in HUVECs through miR-21/PTEN.

Authors:  Jing-Yun Zhang; Jun Ma; Pei Yu; Guang-Jie Tang; Chun-Jun Li; De-Min Yu; Qiu-Mei Zhang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

6.  Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease.

Authors:  Farzaneh Montazerifar; Ali Reza Bakhshipour; Mansour Karajibani; Zahra Torki; Ali Reza Dashipour
Journal:  J Res Med Sci       Date:  2017-05-30       Impact factor: 1.852

7.  Adiponectin, Omentin, Ghrelin, and Visfatin Levels in Obese Patients with Severe Obstructive Sleep Apnea.

Authors:  Dong-Mei Zhang; Xing-Long Pang; Rong Huang; Feng-Ying Gong; Xu Zhong; Yi Xiao
Journal:  Biomed Res Int       Date:  2018-07-29       Impact factor: 3.411

8.  Association between plasma omentin-1 levels in type 2 diabetic patients and peripheral artery disease.

Authors:  Federico Biscetti; Elisabetta Nardella; Nicola Bonadia; Flavia Angelini; Dario Pitocco; Angelo Santoliquido; Marco Filipponi; Raffaele Landolfi; Andrea Flex
Journal:  Cardiovasc Diabetol       Date:  2019-06-05       Impact factor: 9.951

9.  The association between omentin and diabetes: a systematic review and meta-analysis of observational studies.

Authors:  Atefeh As Habi; Malihe Sadeghi; Arman Arab; Hossein Hajianfar
Journal:  Diabetes Metab Syndr Obes       Date:  2019-07-31       Impact factor: 3.168

10.  Serum omentin-1 level in patients with benign prostatic hyperplasia.

Authors:  Haiqing He; Shuiqing Wu; Jun Hao; Long Wang; Kai Ai; Xuan Zhu; Ran Xu; Xiaokun Zhao; Yinhuai Wang; Zhaohui Zhong
Journal:  BMC Urol       Date:  2020-05-06       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.